Capricor Therapeutics (CAPR) News Today $15.04 -0.16 (-1.05%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$15.04 0.00 (0.00%) As of 01/31/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Vanguard Group Inc. Increases Stake in Capricor Therapeutics Inc.January 31 at 1:47 AM | gurufocus.comJPMorgan Chase & Co. Purchases 45,381 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR)JPMorgan Chase & Co. raised its stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 419.5% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 56,199 shares of the biotechnology company's stock after purchasing an additional 45,381 sharJanuary 26, 2025 | marketbeat.comCapricor Therapeutics Inc (NASDAQ:CAPR) Given Consensus Rating of "Buy" by AnalystsJanuary 25, 2025 | americanbankingnews.comResearch Analysts Issue Forecasts for CAPR FY2025 EarningsJanuary 24, 2025 | americanbankingnews.comMagnus Financial Group LLC Invests $276,000 in Capricor Therapeutics Inc (NASDAQ:CAPR)Magnus Financial Group LLC acquired a new stake in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 20,000 shares of the biotechnology company'sJanuary 23, 2025 | marketbeat.comCapricor Therapeutics (NASDAQ:CAPR) delivers shareholders fantastic 54% CAGR over 5 years, surging 12% in the last week aloneJanuary 22, 2025 | uk.finance.yahoo.comBrokers Issue Forecasts for CAPR FY2025 EarningsCapricor Therapeutics Inc (NASDAQ:CAPR - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Capricor Therapeutics in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska anticipates that the biotechnology compaJanuary 22, 2025 | marketbeat.comKrilogy Financial LLC Makes New Investment in Capricor Therapeutics Inc (NASDAQ:CAPR)Krilogy Financial LLC purchased a new position in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 20,800 shares of the biotechnology company's stock, valued atJanuary 20, 2025 | marketbeat.comCapricor Therapeutics Inc (NASDAQ:CAPR) Given Consensus Rating of "Buy" by BrokeragesCapricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) has been assigned a consensus recommendation of "Buy" from the six ratings firms that are covering the firm, MarketBeat reports. Six research analysts have rated the stock with a buy rating. The average twelve-month price objective among anJanuary 20, 2025 | marketbeat.comBarclays PLC Has $552,000 Stake in Capricor Therapeutics Inc (NASDAQ:CAPR)Barclays PLC lifted its stake in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 106.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 36,296 shares of the biotechnology company's stock after buying anJanuary 18, 2025 | marketbeat.comCapricor Therapeutics Inc (NASDAQ:CAPR) Sees Significant Growth in Short InterestCapricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) saw a large increase in short interest in December. As of December 31st, there was short interest totalling 7,950,000 shares, an increase of 42.2% from the December 15th total of 5,590,000 shares. Based on an average trading volume of 1,670,000 shares, the short-interest ratio is presently 4.8 days.January 15, 2025 | marketbeat.comExosome Therapies Market Poised for Explosive Growth During the Study Period (2025-2034) | DelveInsightJanuary 13, 2025 | ca.finance.yahoo.comCapricor Therapeutics (NASDAQ:CAPR) Sees Unusually-High Trading Volume - Time to Buy?Capricor Therapeutics (NASDAQ:CAPR) Sees Large Volume Increase - What's Next?January 3, 2025 | marketbeat.comCapricor Completes Submission Of BLA For Deramiocel For Treatment Of Duchenne Muscular DystrophyJanuary 3, 2025 | markets.businessinsider.comCapricor Therapeutics Stock Surges On BLA Submission for Cell Therapy To Treat Muscular Dystrophy: Retail’s ExcitedJanuary 3, 2025 | msn.comCapricor completes U.S. marketing submission for lead candidateJanuary 2, 2025 | msn.comCapricor Therapeutics: Strategic Advances and Regulatory Progress Drive Buy RatingJanuary 2, 2025 | markets.businessinsider.comCapricor Therapeutics completes submission of BLA to FDA for deramiocelJanuary 2, 2025 | markets.businessinsider.comHC Wainwright Reaffirms "Buy" Rating for Capricor Therapeutics (NASDAQ:CAPR)HC Wainwright restated a "buy" rating and issued a $77.00 price target on shares of Capricor Therapeutics in a research note on Thursday.January 2, 2025 | marketbeat.comCapricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular DystrophyJanuary 2, 2025 | globenewswire.comCapricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Up 26.8% in DecemberCapricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totalling 5,590,000 shares, a growth of 26.8% from the November 30th total of 4,410,000 shares. Based on an average daily volume of 3,570,000 shares, the short-interest ratio is currently 1.6 days.December 29, 2024 | marketbeat.comState Street Corp Has $7.79 Million Position in Capricor Therapeutics Inc (NASDAQ:CAPR)State Street Corp increased its stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 27.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 512,313 shares of the bioteDecember 28, 2024 | marketbeat.comCapricor Therapeutics Inc (NASDAQ:CAPR) Receives Average Rating of "Buy" from BrokeragesCapricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) has earned a consensus recommendation of "Buy" from the six ratings firms that are currently covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average twelve-month price targeDecember 26, 2024 | marketbeat.comCapricor Therapeutics (NASDAQ:CAPR) Trading Down 2.9% - What's Next?Capricor Therapeutics (NASDAQ:CAPR) Shares Down 2.9% - Here's What HappenedDecember 24, 2024 | marketbeat.comCapricor Therapeutics (NASDAQ:CAPR) Trading Up 5.6% - Time to Buy?Capricor Therapeutics (NASDAQ:CAPR) Trading 5.6% Higher - What's Next?December 23, 2024 | marketbeat.comCapricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Up 14.5% in NovemberCapricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) was the target of a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 4,410,000 shares, an increase of 14.5% from the November 15th total of 3,850,000 shares. Based on an average trading volume of 3,430,000 shares, the short-interest ratio is presently 1.3 days.December 16, 2024 | marketbeat.comCapricor Therapeutics (NASDAQ:CAPR) Stock Price Down 5.3% - Time to Sell?Capricor Therapeutics (NASDAQ:CAPR) Shares Down 5.3% - Time to Sell?December 13, 2024 | marketbeat.com250,204 Shares in Capricor Therapeutics Inc (NASDAQ:CAPR) Purchased by Point72 Asset Management L.P.Point72 Asset Management L.P. bought a new stake in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 250,204 shares of the biotechnology company's stock, valued at approDecember 9, 2024 | marketbeat.comDeramiocel's Promise Brightens Capricor's Outlook, With Strings AttachedDecember 7, 2024 | seekingalpha.comCapricor: Additional Deramiocel Data Bodes Well For Initiated Rolling BLA SubmissionDecember 6, 2024 | seekingalpha.comCapricor unlikely impacted by Phan warning letter, says JonesResearchDecember 6, 2024 | markets.businessinsider.comPiper Sandler Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)December 3, 2024 | markets.businessinsider.comCapricor Therapeutics to Present at Upcoming Investor ConferencesDecember 2, 2024 | globenewswire.comCapricor Therapeutics Inc (NASDAQ:CAPR) Receives Average Rating of "Buy" from AnalystsCapricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) has been assigned a consensus recommendation of "Buy" from the six brokerages that are presently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 12-month price targetDecember 1, 2024 | marketbeat.comCapricor Therapeutics Inc (NASDAQ:CAPR) Short Interest UpdateCapricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) was the recipient of a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 3,850,000 shares, a decline of 27.1% from the October 31st total of 5,280,000 shares. Based on an average trading volume of 3,160,000 shares, the short-interest ratio is currently 1.2 days.November 30, 2024 | marketbeat.comOppenheimer Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)November 21, 2024 | markets.businessinsider.comCapricor Therapeutics granted ODD, ATMP status for deramiocel by EMANovember 20, 2024 | markets.businessinsider.comCapricor wins key EU designations for the lead assetNovember 20, 2024 | msn.comCapricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines AgencyNovember 20, 2024 | markets.businessinsider.comJones Trading Initiates Coverage of Capricor Therapeutics (CAPR) with Buy RecommendationNovember 18, 2024 | msn.comCapricor Therapeutics initiated with a Buy at JonesResearchNovember 18, 2024 | markets.businessinsider.comStrong Buy Rating for Capricor Therapeutics Driven by Deramiocel’s Promising Potential in DMD Treatment and Strategic PartnershipsNovember 18, 2024 | markets.businessinsider.comHC Wainwright Brokers Increase Earnings Estimates for CAPRCapricor Therapeutics Inc (NASDAQ:CAPR - Free Report) - HC Wainwright increased their FY2024 EPS estimates for shares of Capricor Therapeutics in a report released on Thursday, November 14th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will post earnings per shNovember 18, 2024 | marketbeat.comCapricor Therapeutics Third Quarter 2024 Earnings: Misses ExpectationsNovember 16, 2024 | finance.yahoo.comCapricor Therapeutics: Promising Developments and Strong Financial Position Drive Buy RatingNovember 16, 2024 | markets.businessinsider.comIs Capricor Therapeutics (CAPR) the Best Multibagger Stock to Buy Heading into 2025?November 16, 2024 | msn.comQ3 2024 Capricor Therapeutics Inc Earnings CallNovember 15, 2024 | finance.yahoo.comCapricor Therapeutics Advances with Strategic ExpansionsNovember 15, 2024 | markets.businessinsider.comCapricor Therapeutics: Strategic Positioning and Financial Stability Drive Buy RatingNovember 15, 2024 | markets.businessinsider.comCapricor Therapeutics (NASDAQ:CAPR) Trading 7.3% Higher After Analyst UpgradeCapricor Therapeutics (NASDAQ:CAPR) Stock Price Up 7.3% After Analyst UpgradeNovember 14, 2024 | marketbeat.com Get Capricor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter. Email Address CAPR Media Mentions By Week CAPR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CAPR News Sentiment▼0.670.69▲Average Medical News Sentiment CAPR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CAPR Articles This Week▼34▲CAPR Articles Average Week Get Capricor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ARWR News Today GMTX News Today HCM News Today MIRM News Today PTGX News Today JANX News Today LGND News Today VERA News Today HRMY News Today SUPN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CAPR) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Capricor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CAPR Stock Alerts